Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Acute Myeloid Leukemia | Research article

Modulation of all-trans retinoic acid-induced MiRNA expression in neoplastic cell lines: a systematic review

Authors: Lara Lima, Thaísa Cristina Tavares de Melo, Diego Marques, Jéssica Nayara Góes de Araújo, Isabela Samária Fernandes Leite, Camila Xavier Alves, Julieta Genre, Vivian Nogueira Silbiger

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

Cancer is a genetic and epigenetic disease that involves inactivation of tumor suppressor genes and activation of proto-oncogenes. All-trans retinoic acid (ATRA) is an isomer of retinoic acid involved in the onset of differentiation and apoptosis of a number of normal and cancer cells, functioning as an anti-cancer agent in several neoplasms. Ectopic changes in the expression of certain microRNAs (miRNAs) occur in response to ATRA, leading to phenotypic alterations in neoplastic cell lines. Moreover, the modulation of miRNA patterns upon ATRA-treatment may represent an effective chemopreventive and anti-cancer therapy strategy. The present systematic review was performed to provide an overview of the modulation of ATRA-induced miRNA expression in different types of neoplastic cells and identify the efficacy of intervention factors (i.e., concentration and duration of treatment) and how they influence expression profiles of oncogenesis-targeting miRNAs.

Methods

A systematic search was conducted according to the PRISMA statement via the US National Library of Medicine MEDLINE/PubMed bibliographic search engine.

Results

The search identified 31 experimental studies involving human cell lines from nine different cancer types (neuroblastoma, acute myeloid leukemia, breast cancer, lung cancer, pancreatic cancer, glioma, glioblastoma, embryonal carcinoma, and colorectal cancer) treated with ATRA at concentrations ranging from 10− 3 μmol/L to 102 μmol mol/L for 24 h to 21 days.

Conclusion

The concentrations used and the duration of treatment of cancer cells with ATRA varied widely. The presence of ATRA in the culture medium of cancer cells was able to modulate the expression of more than 300 miRNAs, and inhibit invasive behavior and deregulated growth of cancer cells, resulting in total tumor remission in some cases. ATRA may thus be broadly effective for neoplasm treatment and prevention, although these studies may not accurately represent in vivo conditions. Additional studies are required to elucidate ATRA-induced miRNA modulation during neoplasm treatment.
Literature
1.
Thun MJ, Delancey JO, Jemal A, Ward EM. The global burden of cancer: priorities for prevention. Carcinogenesis. 2010;31:100–10.CrossRef
2.
Baxter E, Windloch K, Gannon F, Lee JS. Epigenetic regulation in cancer progression. Cell Biosci. 2014;4:1–11.CrossRef
3.
Zhu X, Gao G, Chu K, Yang X, Ren S, Li Y, et al. Inhibition of RAC1-GEF DOCK3 by miR-512-3p contributes to suppression of metastasis in non-small cell lung cancer. Int J Biochem Cell Biol. 2015:1–12.
4.
Chu K, Gao G, Yang X, Ren S. miR-512-5p induces apoptosis and inhibits glycolysis by targeting p21 in non-small cell lung cancer cells. Int J Oncol. 2016;48:577–86.CrossRef
5.
Chen PH, Shih CM, Chang WC, Cheng CH, Lin CW, Ho KH, et al. MicroRNA-320-inhibited E2F3 transcription factor is related to all trans retinoic acid-induced glioma cell. J Neurochem. 2014:731–42.
6.
Bouriez D, Giraud J, Gronnier C, Varon C. Efficiency of all-trans retinoic acid on gastric cancer: a narrative literature review. Int J Mol Sci. 2018;19:1–21.CrossRef
7.
Coyle KM, Dean CA, Thomas ML, Vidovic D, Giacomantonio CA, Helyer L, et al. DNA methylation predicts the response of triple-negative breast cancers to all-trans retinoic acid. Cancers (Basel). 2018;10:1–17.CrossRef
8.
Quiroga PL, Soria EA, Valentich MA, Eynard AR, Quiroga PL, Soria EA, et al. Differential potentiation of retinoic acid effects against human breast cancer cells by unsaturated fatty acids. Nutr Cancer. 2018;70:1137–44.CrossRef
9.
Creutzig U, Dworzak M, Rasche M, Reinhardt D, Hospital C, Medical H. Acute promyelocytic leukemia: new treatment strategies with ATRA and ATO–AML-BFM-recommendations. Klin Padiatr. 2018;230:299–304.CrossRef
10.
Sobas M, Montesinos P, Boluda B, Bernal T, Vellenga E, Nomdedeu J, et al. An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens. Leuk Lymphoma. 2018:1–6.
11.
Krestinina O, Fadeev R, Lomovsky A, Baburina Y, Kobyakova M, Akatov V. Melatonin can strengthen the effect of retinoic acid in HL-60 cells. Mol Sci. 2018;19:1–13.
12.
Walasek A. The new perspectives of targeted therapy in acute myeloid leukemia. Adv Clin Exp Med. 2019;28:271–6.CrossRef
13.
Friesenbichler W, Krizmanich W, Lakatos K, Dworzak M, Amann G, Furtwängler R, et al. Outcome of two patients with bilateral nephroblastomatosis/Wilms tumour treated with an add-on 13-cis retinoic acid therapy – case report. Pediatr Hematol Oncol. 2018;35:218–24.CrossRef
14.
Jobani BM, Najafzadeh N, Mazani M, Arzanlou M, Vardin MM. Molecular mechanism and cytotoxicity of allicin and all-trans retinoic acid against CD44+ versus CD117+ melanoma cells. Phytomedicine. 2018;18:30173–9.
15.
Yu S, Chen H, Chang G, Chen C, Chen H, Singh S, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell. 2008;13:48–57.CrossRef
16.
Waetzig V, Andres C, Frehse S, Herdegen T. Retinoic acid-induced survival effects in SH-SY5Y neuroblastoma cells. J Cell Biochem. 2019;120:5974–86.CrossRef
17.
Zage PE. Novel therapies for relapsed and refractory neuroblastoma. Children. 2018;5:1–27.CrossRef
18.
Peng Y, Croce CM. The role of microRNAs in human cancer. Signal Transduct Target Ther. 2016;1:15004.CrossRef
19.
Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev. 2006;6:857–66.CrossRef
20.
Laneve P, Di Marcotullio L, Gioia U, Fiori ME, Ferretti E, Gulino A, et al. The interplay between microRNAs and the neurotrophin receptor tropomyosin-related kinase C controls proliferation of human neuroblastoma cells. Cell Biol. 2007;104:7957–62.
21.
Evangelisti C, Florian MC, Massimi I, Dominici C, Giannini G, Galardi S, et al. MiR-128 up-regulation inhibits Reelin and DCX expression and reduces neuroblastoma cell motility and invasiveness. FASEB J. 2009;23:4276–87.CrossRef
22.
Das E, Bhattacharyya NP. MicroRNA-432 contributes to dopamine cocktail and retinoic acid induced differentiation of human neuroblastoma cells by targeting NESTIN and RCOR1 genes. FEBS Lett. 2014;588:1706–14.CrossRef
23.
Garzon R, Pichiorri F, Palumbo T, Visentini M, Aqeilan R, Cimmino A, et al. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene. 2007;26:4148–57.CrossRef
24.
Biology C, Sanchez-martínez D, Krzywinska E, Rathore MG, Saumet A, Cornillon A, et al. All-trans retinoic acid (ATRA) induces miR-23a expression, decreases CTSC expression and granzyme B activity leading to impaired NK cell cytotoxicity. Int J Biochem Cell Biol. 2014;49:42–52.CrossRef
25.
Li C, Imai M, Yamasaki M, Hasegawa S, Takahashi N. Effects of pre- and post-administration of vitamin a on the growth of refractory cancers in xenograft mice. Biol Pharm Bull. 2017;40:486–94.CrossRef
26.
Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10:593–601.CrossRef
27.
Khew-goodall Y, Goodall GJ. Myc-modulated miR-9 makes more metastases. Nat Cell Biol. 2010;12:209–11.CrossRef
28.
Li X, Roslan S, Johnstone CN, Wright JA, Bracken CP, Anderson M, et al. MiR-200 can repress breast cancer metastasis through ZEB1-independent but moesin-dependent pathways. Oncogene. 2013:1–12.
29.
Roy SS, Gonugunta VK, Bandyopadhyay A, Rao MK, Goodall GJ, Sun L, et al. Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer. Oncogene. 2013:1–10.
30.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Ioannidis JPA, Clarke M, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.CrossRef
31.
Chen Y, Stallings RL, Chen Y, Stallings RL. Differential patterns of microrna expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res. 2007;67:976–83.CrossRef
32.
Le MTN, Xie H, Zhou B, Chia PH, Rizk P, Um M, et al. MicroRNA-125b promotes neuronal differentiation in human cells by repressing multiple targets. Mol Cell Biol. 2009;29:5290–305.CrossRef
33.
Beveridge NJ, Tooney PA, Carroll AP, Tran N, Cairns MJ. Down-regulation of miR-17 family expression in response to retinoic acid induced neuronal differentiation. Cell Signal. 2009;21:1837–45.CrossRef
34.
Ragusa M, Majorana A, Banelli B, Barbagallo D, Scalia M, Magro G, et al. MIR152, MIR200B, and MIR338, human positional and functional neuroblastoma candidates, are involved in neuroblast differentiation and apoptosis. J Mol Med. 2010:1041–53.CrossRef
35.
Meseguer S, Mudduluru G, Escamilla JM, Allgayer H, Barettino D. MicroRNAs-10a and -10b contribute to retinoic acid-induced differentiation of neuroblastoma cells and target the alternative splicing regulatory factor SFRS1 (SF2/ASF ). J Biol Chem. 2011;286:4150–64.CrossRef
36.
Das S, Foley N, Bryan K, Watters KM, Bray I, Murphy DM, et al. MicroRNA mediates DNA demethylation events triggered by retinoic acid during neuroblastoma cell differentiation. Mol Cell Pathobiol. 2010;70:7874–82.
37.
Das S, Bryan K, Buckley PG, Piskareva O, Bray IM, Foley N, et al. Modulation of neuroblastoma disease pathogenesis by an extensive network of epigenetically regulated microRNAs. Oncogene. 2013;32:2927–36.CrossRef
38.
Chen H, Shalom-feuerstein R, Riley J, Zhang S, Tucci P, Agostini M, et al. miR-7 and miR-214 are specifically expressed during neuroblastoma differentiation, cortical development and embryonic stem cells differentiation, and control neurite outgrowth in vitro. Biochem Biophys Res Commun. 2010;394:921–7.CrossRef
39.
Foley NH, Bray I, Watters KM, Das S, Bryan K, Bernas T, et al. MicroRNAs 10a and 10b are potent inducers of neuroblastoma cell differentiation through targeting of nuclear receptor corepressor 2. Cell Death Differ. 2011;18:1089–98.CrossRef
40.
Marchis ML, De BM, Salvatori B, Puzzolo MC, Bozzoni I, Fatica A. A new molecular network comprising PU.1, interferon regulatory factor proteins and miR-342 stimulates ATRA-mediated granulocytic differentiation of acute promyelocytic leukemia cells. Leukemia. 2009;23:856–62.CrossRef
41.
Gao S, Yang J, Chen C, Zhang S, Xing C, Li H. miR-15a/16–1 enhances retinoic acid-mediated diff erentiation of leukemic cells and is up-regulated by retinoic acid. Leuk Limphona. 2011;52:2365–71.CrossRef
42.
Lin K, Zhang X, Feng D, Zhang H, Zeng C, Han B, et al. miR-125b, a target of CDX2, regulates cell differentiation through repression of the core binding factor in hematopoietic malignancies. J Biol Chem. 2011;286:38253–63.CrossRef
43.
Morris VA, Zhang A, Yang T, Stirewalt DL, Ramamurthy R, Oehler VG. MicroRNA-150 expression induces myeloid differentiation of human acute leukemia cells and normal hematopoietic progenitors. PLoS One. 2013;8:e75815.CrossRef
44.
Zhuang LK, Xu GP, Pan XR, Lou YJ, Zou QP, Xia D, et al. MicroRNA-181a-mediated downregulation of AC9 protein decreases intracellular cAMP level and inhibits ATRA-induced APL cell differentiation. Cell Death Dis. 2014;5:e1161.CrossRef
45.
Lin Y, Li D, Liang Q, Liu S, Zuo X, Li L, et al. miR-638 regulates differentiation and proliferation in leukemic cells by targeting cyclin-dependent kinase 2. J Biol Chem. 2015;290:1818–28.CrossRef
46.
Bräuer-hartmann D, Hartmann J, Wurm AA, Gerloff D. PML/RARα-regulated miR-181a/b-cluster targets the tumor suppressor RASSF1A in acute promyelocytic leukemia. Cancer Res. 2016;75:3411–24.CrossRef
47.
Yan Y, Hanse EA, Stedman K, Benson JM, Lowman XH, Subramanian S, et al. Transcription factor C/EBP-β induces tumor-suppressor phosphatase PHLPP2 through repression of the miR-17–92 cluster in differentiating AML cells. Cell Death Differ. 2016;23:1232–42.CrossRef
48.
Terao M, Fratelli M, Kurosaki M, Zanetti A, Guarnaccia V, Paroni G, et al. Induction of miR-21 by retinoic acid in estrogen receptor-positive breast carcinoma cells: biological correlates and molecular targets. J Biol Chem. 2011;286:4027–42.CrossRef
49.
Khan S, Wall D, Curran C, Newell J, Kerin MJ, Dwyer RM. MicroRNA-10a is reduced in breast cancer and regulated in part through retinoic acid. BMC Cancer. 2015;15:345.CrossRef
50.
Fisher JN, Terao M, Fratelli M, Kurosaki M, Paroni G, Zanetti A, et al. MicroRNA networks regulated by all-trans retinoic acid and Lapatinib control the growth, survival and motility of breast cancer cells. Oncotarget. 2015;6:13176–200.PubMedPubMedCentral
51.
Weiss FU, Marques IJ, Woltering JM, Vlecken DH, Aghdassi A, Partecke LI, et al. Retinoic acid receptor antagonists inhibit mir-10a expression and block metastatic behavior of pancreatic cancer. Gastroenterology. 2009;137:2136–45.CrossRef
52.
Xia H, He T, Liu C, Cui Y, Song P, Jin X, et al. MiR-125b expression affects the proliferation and apoptosis of human glioma cells by targeting Bmf. Cell Physiol Biochem. 2009;23:347–58.CrossRef
53.
Chen P-H, Shih C-M, Chang W-C, Cheng C-H, Lin C-W, Ho K, et al. MicroRNA-320-inhibited E2F3 transcription factor is related to all trans retinoic acid-induced glioma cell apoptosis. J Neurochem. 2014;131:731–42.CrossRef
54.
Chen Y, Meng L, Yu Q, Dong D, Tan G, Huang X, et al. The miR-134 attenuates the expression of transcription factor FOXM1 during pluripotent NT2/D1 embryonal carcinoma cell differentiation. Exp Cell Res. 2015;330:442–50.CrossRef
55.
Liu W, Song Y, Zhang C, Gao P, Huang B. The protective role of all-transretinoic acid (ATRA) against colorectal cancer development is achieved via increasing miR-3666 expression and decreasing E2F7 expression. Biomed Pharmacother. 2018;104:94–101.CrossRef
56.
Su M, Alonso S, Jones JW, Yu J, Kane MA, Jones J, et al. All-trans retinoic acid activity in acute myeloid leukemia: role of cytochrome P450 enzyme expression by the microenvironment. PLoS One. 2015;10:e0127790.CrossRef
57.
Cogan T, Cogan M, Tamil L. RAMS: remote and automatic mammogram screening. Comput Biol Med. 2019;107:18–29.CrossRef
Metadata
Title
Modulation of all-trans retinoic acid-induced MiRNA expression in neoplastic cell lines: a systematic review
Authors
Lara Lima
Thaísa Cristina Tavares de Melo
Diego Marques
Jéssica Nayara Góes de Araújo
Isabela Samária Fernandes Leite
Camila Xavier Alves
Julieta Genre
Vivian Nogueira Silbiger
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-6081-7

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue

Research article

Analysis on GENIE reveals novel recurrent variants that affect molecular diagnosis of sizable number of cancer patients

Research article

Prophylactic HIPEC with radical D2 gastrectomy improves survival and peritoneal recurrence rates for locally advanced gastric cancer: personal experience from a randomized case control study

Study protocol

The chemo-gut study: investigating the long-term effects of chemotherapy on gut microbiota, metabolic, immune, psychological and cognitive parameters in young adult Cancer survivors; study protocol

Case report

Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report

Research article

Reduced FRG1 expression promotes prostate cancer progression and affects prostate cancer cell migration and invasion

Case report

Identification of a metastatic lung adenocarcinoma of the palate mucosa through genetic and histopathological analysis: a rare case report and literature review
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits